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Preinvasive colorectal lesion transcriptomes correlate with
endoscopic morphology (polypoid vs. nonpolypoid)
Abstract
Improved colonoscopy is revealing precancerous lesions that were frequently missed in the past, and
∼30% of those detected today have nonpolypoid morphologies ranging from slightly raised to depressed.
To characterize these lesions molecularly, we assessed transcription of 23,768 genes in 42 precancerous
lesions (25 slightly elevated nonpolypoid and 17 pedunculated polypoid), each with corresponding
samples of normal mucosa. Nonpolypoid versus polypoid morphology explained most gene expression
variance among samples; histology, size, and degree of dysplasia were also linked to specific patterns.
Expression changes in polypoid lesions frequently affected cell-cycling pathways, whereas cell-survival
dysregulation predominated in nonpolypoid lesions. The latter also displayed fewer and less dramatic
expression changes than polypoid lesions. Paradigmatic of this trend was progressive loss through the
normal > nonpolypoid > polypoid > cancer sequence of TMIGD1 mRNA and protein. This finding,
along with TMIGD1 protein expression patterns in tissues and cell lines, suggests that TMIGD1 might
be associated with intestinal-cell differentiation. We conclude that molecular dysregulation in slightly
elevated, nonpolypoid, precancerous colorectal lesions may be somewhat less severe than that observed
in classic adenomatous polyps.
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Improved colonoscopy is revealing precancerous lesions that were frequently
missed in the past, and 30% of those detected today have nonpolypoid
morphologies ranging from slightly raised to depressed. To characterize these
lesions molecularly, we assessed transcription of 23,768 genes in 42 precancer-
ous lesions (25 slightly elevated nonpolypoid and 17 pedunculated polypoid),
each with corresponding samples of normal mucosa. Nonpolypoid versus poly-
poid morphology explained most gene expression variance among samples;
histology, size, and degree of dysplasia were also linked to speciﬁc patterns.
Expression changes in polypoid lesions frequently affected cell-cycling pathways,
whereas cell-survival dysregulation predominated in nonpolypoid lesions.
The latter also displayed fewer and less dramatic expression changes than
polypoid lesions. Paradigmatic of this trend was progressive loss through the
normal>nonpolypoid> polypoid> cancer sequence of TMIGD1 mRNA and
protein. This ﬁnding, along with TMIGD1 protein expression patterns in tissues
and cell lines, suggests that TMIGD1 might be associated with intestinal-cell
differentiation. We conclude that molecular dysregulation in slightly elevated,
nonpolypoid, precancerous colorectal lesions may be somewhat less severe than
that observed in classic adenomatous polyps.
INTRODUCTION
Two decades of in-depth investigation have shed important light
on the complexity and heterogeneity of human colorectal
cancer. Several distinct phenotypes have been identiﬁed at the
clinical, histologic and molecular levels, and the differences can
also be observed in premalignant colorectal lesions. Once
referred to collectively as colorectal polyps, these precursor
lesions are now classiﬁed at endoscopy as polypoid and
nonpolypoid. The former category comprises lesions that
protrude into the gut lumen, including pedunculated and sessile
forms. At the other end of the spectrum are the nonpolypoid
lesions, which are still widely referred to as ‘ﬂat’. Most are
actually slightly elevated above the mucosal surface. Mildly
depressed forms are rare, but even small lesions of this type are
generally farther along the road to cancer than their slightly
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elevated counterparts (Endoscopic Classiﬁcation Review Group,
2005; Soetikno et al, 2008). O’Brien et al highlighted the impact
of this new terminology in their reassessment of superﬁcial
neoplasms classiﬁed as polyps in the United States National
Polyp Study. Around 30% of these tumours met the new criteria
for nonpolypoid lesions, including two-thirds of those originally
labelled sessile polyps (O’Brien et al, 2004). A similar picture
emerged from recent studies (Kudo et al, 2008, and references
herein), many of which employed high-resolution colono-
scopes, magniﬁcation, and chromoendoscopy.
The more accurate classiﬁcation of premalignant lesions in
terms of their appearance at endoscopy has led to some
important observations. For example, true polypoid lesions are
more frequently detected in the distal colon (from the splenic
ﬂexure to the rectum), whereas nonpolypoid neoplasms are
more common in the proximal colon (from the cecum to the
splenic ﬂexure). Furthermore, while most nonpolypoid lesions
exhibit adenomatous changes with variable degrees of cellular
dysplasia (like their polypoid counterparts), others display
infolding of the glandular epithelium that produces a saw-
toothed (or serrated) pattern in longitudinally sectioned
epithelial crypts (Snover et al, 2005). These serrated lesions
include morphologically distinct subsets (e.g. with or without
dysplasia), and many present molecular alterations that are rare
in adenomas, such as BRAF mutations or the CpG island
methylator phenotype, which is characterized by silencing of
several cancer-relevant gene promoters (O’Brien, 2007). The
DNA mismatch repair gene MLH1 is a very common target of
CpG island methylation (Herman et al, 1998). Its silencing
transforms precursor lesions into mismatch repair-deﬁcient
adenocarcinomas, which are almost always located in the
proximal colon and occur 5–10 years later than other sporadic
colorectal cancers.
The present study was designed to test the hypothesis that
morphological differences among precancerous colorectal
lesions reﬂect distinct tumourigenic pathways. To this end,
we compared the global gene expression proﬁle of nonpolypoid
preinvasive lesions (whose roles in colon tumourigenesis are
still poorly understood) with those of normal colonic mucosa
and polypoid lesions.
RESULTS
As shown in Table 1, the endoscopic criteria used for lesion
collection (see Materials and Methods) provided us with two
relatively homogeneous tissue groups. The 17 pedunculated
polypoid lesions [type Ip in the Paris classiﬁcation (Paris
Workshop Participants, 2003)] were taken from all segments of
the colorectum, and all were adenomas. On the whole, they
were appreciably smaller than the 25 slightly elevated
nonpolypoid lesions (type IIa; mean diameters: 23.3mm vs.
29mm, respectively), which were deliberately collected from
the proximal colon. The aim of this restriction was to maximize
the chances of obtaining lesions associated with a nonadeno-
matous pathway of tumourigenesis (see Introduction). In fact, 5
(20%) of the nonpolypoid lesions exhibited serrated histology,
including 3 that were nondysplastic. The other 20 were
adenomas with some degree of cellular dysplasia (Table 1).
High-degree dysplasia was more common in the nonpolypoid
group (n¼ 7, 28% vs. n¼ 3, 17.6% of the polypoid lesions), but
this difference is probably related to the larger size of the type IIa
lesions (see above). The highly dysplastic lesions with polypoid
morphology were much smaller than their counterparts in
the nonpolypoid group (mean diameters: 25mm vs. 40mm,
respectively). Three of the 5 serrated lesions harboured a BRAF
V600E mutation (as expected), but none exhibited epigenetic
silencing of MLH1 (Supporting Information Table 1).
Expression of 23,768 transcript clusters was analysed in all 42
precancerous lesions and their corresponding samples of
normal mucosa (see Materials and Methods and Supporting
Information). Unsupervised principal component analysis
(PCA; Fig 1A) demonstrated that much of the variance among
the samples was due to interindividual variability (PC axis 1,
PC1), but a considerable portion of the residual variance was
accounted for by tissue type (i.e. normal mucosa, polypoid
lesions and nonpolypoid lesions; PC2). This variable was
therefore used as the prime grouping factor in the supervised
between-group analysis (BGA) based on correspondence
analysis (CoA; Fig 1B). Normal mucosa samples were clearly
segregated from the precancerous lesions, and the polypoid and
nonpolypoid subsets within the latter category were also clearly
distinct. [These distinctions were still evident after exclusion
from the BGA of the three nondysplastic serrated lesions
(Supporting Information Fig 1).]
To identify other clinical variables that would explain the
detected gene expression changes, we reduced the noise of the
interindividual variability that had emerged from both the BGA
and PCA. To this end, transcript levels were expressed as ratios
of the lesional value to the basal level observed in the
corresponding sample of normal mucosa. These log2 ratio
expression values were then subjected to redundancy analysis
(RDA), in which clinical descriptors (tissue type, sex, age,
histology, diameter, and degree of dysplasia) were independent
(or explanatory) variables, and the gene expression proﬁle was
the dependent (or explained) variable predicted by the clinical
descriptors (Supporting Information). As shown in Fig 2A, over
half (53.2%) of the total variance in this data set was explained
by four variables—tissue type, histology, diameter, and degree of
dysplasia. The most important was tissue type (i.e. nonpolypoid
vs. polypoid lesions): it was described by the longest vectors,
which pointed in opposite directions, reﬂecting the negative
correlations between nonpolypoid and polypoid lesions for gene
expression. A map of the sample scores and the 20 genes whose
expression levels most effectively discriminated between
polypoid and nonpolypoid lesions are shown in Fig 2B.
(The top 200 discriminating genes are listed in Supporting
Information Table 2.)
Polypoid and nonpolypoid lesions differed signiﬁcantly in
terms of the numbers of genes with expression levels different
from those in normal mucosa, and this signiﬁcance persisted at
various false discovery rates (FDR 0.001–0.05; Supporting
Information Fig 2). Genes altered in both groups of lesions
represented over half of those dysregulated in nonpolypoid
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Table 1. Characteristics of the 37 patients with nonpolypoid and polypoid precancerous lesions included in the study (42 lesions).
Patienta Age Sex Colon
segment
involvedb
Maximum
lesion diameter
(mm)
Macroscopic
appearancec
Pit
patternd
Microscopic
appearancee
Dysplasiaf No. lesions
presentg
Nonpolypoid
1a 75 F Tra 70 IIa-IIb 3S-3L VA high 7
1b Tra 20 IIa 3S-3L VA high
2a 72 F Cec 30 IIa 4 TA low 9
2b Tra 20 IIa 3S-3L TA low
3 75 F Tra 40 IIa-IIc 3S-3L TA high 1
4 73 F Asc 40 IIa-IIc 2-3L SA (mixed) 6¼ high 1
5 44 M HF 35 IIa 3S-3L TA low 2
6 79 F Asc 20 IIa 4 TA low 1
7 67 F Asc 20 IIa 3L TA low 1
8 48 M HF 15 IIa 3L TA low 1
9 69 F Asc 40 IIa 3L TVA low 1
10 83 M Asc 25 IIa 3L TA low 4
11 66 M Cec 25 IIa 3L TA high 2
12 79 M Asc 35 IIa-IIc 5N TVA high 2
13a 54 F Cec 45 IIa 3L TVA low 16
13b Asc 12 IIa 3L TA low
14 74 F Cec 50 IIa 3L TVA low 1
15 62 F Asc 15 IIa 3S-3L SA (mixed) low 1
16 52 F Tra 15 IIa 2 SSA 6¼ no dysplasia 1
17a 54 F Cec 50 IIa 2-3L TA high 2
17b Asc 20 IIa 2-3L TA low
18 72 M Asc 25 IIa 3S-3L TA low 1
19a 79 M Asc 25 IIa 3L VA low 3
20 47 M Asc 20-25 IIa-IIc 3S-3L MVSP 6¼ no dysplasia 3
21 66 M Asc 12 IIa 3L MVSP no dysplasia 1
Polypoid
22 64 F Asc 15 Ip nr TA low 2
23 56 M Asc 15 Ip nr TA low 2
24 79 M Asc 20 Ip nr TVA low 3
25 27 M Asc 15 Ip nr TVA high 3
26 40 F Sig 30 Ip nr TVA low 51 x
27 83 M Sig 12 Ip nr TVA low 3
28 50 M Sig 30 Ip nr TVA high 3
29 74 F Sig 20 Ip nr TVA low 1
30 69 M Rec 40 Ip nr TA low 3
31 69 M Sig 30 Ip nr TA low 7
32 56 M Sig 30 Ip nr TA low 3
33 58 F Des 20 Ip nr TA low 3
34 52 F Sig 30 Ip nr TA low 3
35 69 F Sig 15 Ip nr TVA low 3
36 58 F Asc 15 Ip nr TVA low 1
19b 79 M Tra 30 Ip nr VA low 3
37 73 M Asc 30 Ip nr TVA high 1
aTwo lesions were analyzed from patients marked with an asterisk.
bAbbreviations: Cec, cecum; Asc, ascending colon; HF, hepatic ﬂexure; Tra, transversum; Des, descending colon; Sig, sigma; Rec, rectum.
cClassiﬁed according to the Paris Endoscopic Classiﬁcation of Superﬁcial Neoplastic Lesions (Paris Workshop Participants, 2003). All nonpolypoid lesions were
slightly elevated (type IIa); a few also included a small region that was completely ﬂat (IIb) or depressed (IIc).
dKudo classiﬁcation of colonic crypt morphology (Kudo et al, 2001). Abbreviations: nr, Pit pattern not reported by the endoscopist.
eAbbreviations: TA, tubular adenoma; TVA, tubulovillous adenoma; VA, villous adenoma; MVSP, microvescicular serrated polyp; SA, serrated adenoma; SSA, sessile
serrated adenoma. 6¼, Lesions carrying BRAFV600E mutation (valine to glutamate substitution at codon 600).
fHighest degree of dysplasia in the lesion based on the WHO classiﬁcation of tumors of the digestive system (Editorial and consensus conference in Lyon, France,
November 6-9, 1999 [IARC]).
gTotal number of lesions noted during the study colonoscopy, including those used in the present study. x, Patient with suspected attenuated polyposis. The
mutational analysis of the APC and MYH genes is currently not available.
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lesions and a lower proportion of those that were differentially
expressed in polypoid lesions. In most cases, the direction of the
alteration (upregulation/downregulation) was the same in both
groups.
Because all our nonpolypoid lesions came from the proximal
colon (i.e. not beyond the splenic ﬂexure), some of the
differences they exhibited with respect to the polypoid lesions
(which came from all parts of the colon and rectum) might be
related to their location instead of their morphology. In fact,
gene expression proﬁles within our polypoid lesion group
displayed obvious colon-segment-related differences (as
expected; Supporting Information Fig 3). Nonetheless, the
distal colon and proximal colon subsets in this group were both
clearly distinguishable from the nonpolypoid lesions. Further-
more, when tissue type and locationwere included in a two-way
ANOVA as potentially interacting factors, most of the genes
whose expression levels discriminated between the nonpoly-
poid and polypoid lesion groups were found to be unrelated to
the colon segment of origin (Supporting Information Table 2).
Speciﬁc gene expression patterns were also associated with
lesion histology, size, and degree of dysplasia (Fig 3). Diameter
and degree of dysplasia were signiﬁcantly associated with
distinct expression proﬁle clusters, which conﬁrms our previous
observations (Sabates-Bellver et al, 2007) in 32 polypoid lesions
analysed with a different microarray platform. However, as
shown in Fig 3A, the present analysis also revealed that serrated
and adenomatous lesions are clearly distinct at the transcrip-
tome level.
The transcriptomes of polypoid and nonpolypoid lesions
were also analysed to identify the molecular pathways that are
dysregulated in the two types of tissues. As shown in Fig 4A, the
pathways altered in polypoid lesions were predominantly
concerned with cell-cycle regulation, whereas alterations in
oxidative phosphorylation, ubiquinone metabolism, and IGF-1
signalling were more characteristic of the nonpolypoid trans-
formation process. Other pathways exhibited similar degrees of
dysregulation in the two types of lesions, including the Wnt
signalling cascade (Fig 4B). The latter ﬁnding was conﬁrmed by
the results of immunohistochemical assessment of b-catenin
expression (Supporting Information Fig 4).
TMIGD1 ranked very high on the list of genes whose
expression levels varied markedly with tissue type (Fig 2B),
lesion size, and histology (Fig. 3; Supporting Information Table
2). The constant representation of this gene in the multivariate
analyses reported thus far reﬂects its progressive downregula-
tion as transformation advances. As shown in Fig 5A, its
expression was clearly decreased in nonpolypoid lesions (fold-
change; FC vs. normal mucosa: 19), but the downregulation
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Figure 1. Principal component and between-group analyses of gene
expression data for the 84 colorectal tissue samples.
A. Three-dimensional PCA score plot of log2 expression intensity values for
the 42 normal mucosa samples (red spheres); 25 nonpolypoid lesions
(blue); and 17 polypoid lesions (green). The first three principal
components (PCs) account for 50.3% of total variance. PC axis 1 (PC1), the
main direction of spread within all three tissue groups, reflects intragroup,
interindividual variability. PC2 reflects intergroup variance based on tissue
type, the factor responsible for segregating specimens into three groups.
No specific biological variables correlated with the variance explained by
PC3 (<5% of total) or the remaining variance in the data set (49.7% of the
total). The data quality andmodel reliability are reflected in the absence of
outliers and the high proportion of variance explained by PCs 1 and 2
(46.3% vs. 25% in a randomized PCA model of this set of samples and
genes).
B. BGA based on correspondence analysis (CoA) of log2 gene expression
intensity values for samples grouped by tissue type. CoA discriminated
between normal and lesional samples (axis 1) and between polypoid
and nonpolypoid lesions (axis 2). The dispersion of scores along axis 2
reflects high-interindividual variability. Lower panel: Projection of scores
on axis 1.
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was much more evident in polypoid lesions (FC 66) and even
more dramatic in a small series of advanced cancers (FC 125)
we recently examined with exon arrays.
This trend has never been described (probes for this gene
were not present in previous-generation microarray platforms),
and the function of TMIGD1 is unknown, so we attempted to
better characterize the expression pattern of this gene in
colorectal and other tissues. Real time quantitative polymerase
chain reaction (after reverse transcription) (RT-PCR) analysis
(Fig 5B) conﬁrmed that TMIGD1 transcription was signiﬁcantly
decreased in the precancerous and cancerous lesions we
examined with microarrays [compared with normal mucosal
expression in different segments of the colon, the rectum (data
not shown), and the terminal ileum]. TMIGD1 transcript was
also found in normal epithelial cells from the kidney and trachea
(Supporting Information Fig 5).
Promoter hypermethylation does not seem to be the cause of
the downregulated TMIGD1 expression. The TMIGD1 promoter
lacks canonical CpG islands whose epigenetic alteration can
repress transcription. Furthermore, treatment of the TMIGD1-
negative colon cancer cell line Co115 with a DNA methyl-
transferase inhibitor (5-aza-20 deoxycytidine) and a histone
deacetylase inhibitor (trichostatin A) had no effect on TMIGD1
expression (data not shown). Using the TRANSFAC database
(Matys et al, 2003), we identiﬁed several putative transcription
factor binding sites (TFBSs) around the transcription start site of
TMIGD1. Three of these sequences were predicted to bind
factors encoded by the MEIS1, HNF4A, and NFE2L1 genes,
which were transcriptionally underexpressed in the precancer-
ous lesions (Supporting Information Fig 6). HNF4A has been
shown to upregulate the expression of murine Tmigd1
(Ishikawa et al, 2008), and a recent genome-wide ChIP-chip
study in human hepatoma cells (HepG2) identiﬁed an HNF4A
binding site distal to the TMIGD1 start site (Wallerman et al,
2009). These ﬁndings are interesting because the HNF4
transcription factor family seems to regulate the expression of
numerous cell differentiation-induced genes in the enterocytes
of small intestinal villi in mice (Stegmann et al, 2006). Our data
therefore raise the possibility that TMIGD1 expression is
somehow associated with differentiation of intestinal epithelial
cells.
Immunohistochemistry studies revealed TMIGD1 protein
levels that paralleled those of TMIGD1 transcript. In normal
colorectal mucosa, the protein is conﬁned mainly to the upper
crypt compartments, which contain differentiated cells (Fig 6);
no expression was noted in the proliferative crypt compartment.
Similar patterns were observed in the small intestine, where
TMIGD1 expression was limited to the villi (and was maximal at
the brush border), and in the kidney (Supporting Information
Fig 7). In line with our gene expression data, TMIGD1
expression in colorectal tissues diminished markedly in
precancerous and malignant lesions, paralleling losses of
differentiation in these tissues (Fig 6).
The speciﬁcity of the antibody used in these studies was
ascertained with Western blot and immunocytochemistry
experiments performed in SW480 colon cancer cells transfected
Research Article
The transcriptome of preinvasive colorectal tumours
Figure 2. Clinical and pathologic variables that predict the gene
expression changes.
A. Redundancy analysis (RDA). Correlation circle (based on log2 ratio
expression intensity values) illustrates the proportion of total variance
supported by different variables, each depicted as a vector. Vector length
(maximum: radius of the circle) reflects the variable’s relevance in the
reduced coordinate system defined by RDA axes 1 and 2; vector direction
reflects intervariable correlations (e.g. oppositely oriented vectors
represent negatively correlated variables). Most of the variance in this data
set was explained by tissue type (polypoid vs. nonpolypoid), followed by
histology (adenomatous vs. serrated), degree of dysplasia (no dysplasia, low
and high degree of dysplasia), and lesion diameter.
B. Left: BGA of log2 ratio expression intensity values grouped by tissue type
(nonpolypoid vs. polypoid). When grouping is based on a dichotomous
variable like this, only the scores on BGA axis 1 are meaningful. Right: The
20 genes whose expression levels were mostly responsible for segregation
of polypoid and nonpolypoid samples are plotted along the same BGA axis
1 (ranked according to score magnitude—positive or negative—on axis 1,
which is proportional to the distance from the center of the axes to the
correlation circle).
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Figure 3. Pathologic features of precancerous lesions that correlate with specific gene expression profiles. Correlation circles (left) and BGA plots (right) for
variables identified by RDA as the second (A), third (B) and fourth (C) most significant predictors of gene expression patterns (after tissue type; Fig 2).
A. Lesion histology (adenomatous vs. serrated). One-dimensional plot of scores on BGA axis 1with the top 20 genes responsible for this discrimination (see Fig 2 for
details).
B. Lesion diameter (four size groups). For nondichotomous classifiers like this (and dysplasia, shown in panel C), scores on BGA axes 1 and 2 are meaningful, and
results are visualized as biplots. Each size group is delimited by a probability ellipse (reflecting the two-dimensional 67% boundaries of a gaussian distribution,
i.e. 1 standard deviation unit) with a labelled centroid. Along BGA axis 2, the red and blue ellipses representing smaller lesions (diameter30mm) are clearly
separated from those representing larger (31mm) lesions (green and brown). The top 20 genes responsible for segregating these lesions into these two
categories are listed on the graph.
C. Degree of dysplasia (high vs. low vs. absent). Lesions with high and low degrees of dysplasia (black and red ellipses, respectively), are completely segregated on
axis 2, and the 20 genes that most responsible for this separation are reported. Lesions with and without dysplasia are segregated along axis 1. Results are
visualized only for the genes with highest positive (TMIGD1) and negative (CLCA1) scores.
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Figure 4. Cellular pathways that play major roles in the development of polypoid versus nonpolypoid precancerous lesions of the colon. Two lists of genes
whose expression was significantly altered (p< 0.05 vs. normal mucosa) in polypoid and nonpolypoid lesions were analysed with the GeneGo MetaCore software
(www.genego.com; St. Joseph, MI, USA), which assigned each gene to a specific cellular pathway on the basis of data available in the Gene Ontology catalogue
(Ashburner et al, 2000). We calculated the proportion of total genes in a given pathway that were differentially expressed. The statistical significance of the
involvement of a given pathway is positively related to this proportion (p-value on the x-axis). Green and blue bars refer to polypoid and nonpolypoid lesions,
respectively (compared with the corresponding normal mucosa).
A. The 10 pathways whose dysregulation in polypoid differed most markedly from that observed in nonpolypoid lesions. For example, in nonpolypoid lesions 50%
(49/98) of the genes involved in oxidative phosphorylation were differentially expressed (vs. normal mucosa) compared with only 15% (15/98) in polypoid
lesions.
B. The 10 pathways whose dysregulation in polypoid lesions was most similar to that observed in nonpolypoid lesions.
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with TMIGD1 cDNA (Fig 7A and B). The results indicate that
TMIGD1 is a nonsecreted, glycosylated protein located in the
cytoplasm and cell membrane. Its possible relation to cell
differentiation was explored in Caco2 colon cancer cells, where
persistent contact-mediated inhibition of growth triggers
differentiation towards the absorptive intestinal cell lineage
(Peterson & Mooseker, 1992) reﬂected by increased expression
of the differentiation marker VIL1. As shown in Fig 7C,
conﬂuence-induced differentiation in these cells was accom-
panied by increasingly marked upregulation of TMIGD1
transcription and mildly increased expression of the corre-
sponding protein, which was undetectable in extracts from log-
phase Caco2 cells (Fig 7D).
DISCUSSION
Not all precancerous colorectal lesions develop into carcinomas.
This fate is more commonly seen in depressed (type IIc) lesions
(Endoscopic Classiﬁcation Review Group, 2005; Soetikno et al,
2008), but this subset includes only 1% of all precancerous
lesions. Type-IIa nonpolypoid lesions, which are slightly
elevated above the mucosal surface, are much more common.
For several reasons, they, too, are commonly believed to be
more likely to undergo malignant transformation than polypoid
lesions. For one thing, they are easier to miss during standard
colonoscopy (especially those located in the proximal colon;
Lambert et al, 2009, and references herein). In addition,
epigenetic silencing of the DNA mismatch repair gene MLH1
seems to be particularly frequent in nonpolypoid lesions in the
proximal colon (O’Brien, 2007, and references herein). (Mis-
match repair deﬁciency dramatically increases mutation rates,
and this is believed to markedly accelerate the transformation
process.) And ﬁnally, Soetikno et al have reported a frequency of
in situ or submucosal carcinoma in nondepressed, nonpolypoid
lesions that was four times higher than that observed in
polypoid lesions (Soetikno et al, 2008).
Reliable characterization of the malignant potential of
nonpolypoid lesions requires high-throughput molecular analysis
of large numbers of lesions. Our study represents the ﬁrst attempt
to ﬁll this gap. We investigated the entire complement of RNA
transcripts in 25 nonpolypoid precancerous lesions and compared
the results with those obtained in corresponding specimens of
normal colonic mucosa and in 17 polypoid lesions (A total of 84
samples were investigated, a relatively large series for this type of
study.) The exon array platform we used explores the expression
of all exons, annotated and putative, in the human genome. We
limited the present data analysis to a subset of 23,768 well-
annotated genes, because our main interest lies in expression
changes involving proteins or regulatory RNAs with potential
roles in the transformation process. When we extended our
analysis to the 235,234 non-annotated transcript clusters (many of
which probably represent noncoding genomic regions), the
discriminatory power of the expression changes dropped sharply
(data not shown). We also excluded data on the expression of
alternatively spliced transcript isoforms. This information can be
obtained with the exon platform, but we have found serious
limitations in the software tools available for its analysis.
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Figure 5. TMIGD1 mRNA expression in colorectal tissues and cancer cell
lines.
A. Normalized log2 expression intensity values of TMIGD1mRNA detected by
exon array analysis in polypoid and nonpolypoid precancerous lesions
(green and blue dots, respectively). Grey dots: Corresponding values for six
colorectal cancers recently investigated with the same arrays. Results are
expressed as fold changes (FCs) versus values observed in corresponding
samples of normal mucosa (red dots). Box plots show 25th, 50th (median),
and 75th percentiles of lesional expression values.
B. Real time quantitative RT-PCR confirmed TMIGD1 mRNA expression levels
in the colorectal tissues investigated in the microarray study. Transcript
was also detected in the normal terminal ileum and in several cell lines.
Other cell lines (SW480, Colo741, HT29, HT29M6, Co115, SW48, CX1,
SW837, HCT116, SW620, Vaco481, SW403, LnCaP, MCF7, Hela, BEAS2B,
U2OS, HEK293T, A2780, LAN-1, and Sk-N-SH) did not express TMIGD1.
TMIGD1 (target) and GAPDH (reference) coding regions were amplified.
y-axis: [target concentration/reference concentration] for sample/[target
concentration/reference concentration] for normal mucosa.
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The clinical variable that explained the largest proportion of
the variation in our data set was tissue type. This means that the
transcriptomes of nonpolypoid and polypoid lesions are not
only different from that of the normal mucosa: they can also be
readily distinguished from one another. At the molecular level,
nonpolypoid lesions differed from their polypoid counterparts in
two respects.
The ﬁrst was quantitative. As shown in Supporting Informa-
tion Fig 2, compared with the polypoid lesions, those in the
nonpolypoid group had fewer genes displaying transcript levels
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Figure 6. Immunohistochemical staining of normal and neoplastic colonic tissues with antibodies against TMIGD1.
A. In normal mucosa, TMIGD1 expression is limited to the upper portion of the epithelial crypts, where differentiated cells are located.
B. Higher magnification views of TMIGD1 staining at base of a colonic crypt.
C. Higher magnification views of TMIGD1 staining at mouth of a colonic crypt. TMIGD1 is located in the cytoplasm and probably in the cell membrane.
D. Its expression wasmarkedly reduced in nonpolypoid lesions. The inset shows different levels of expression at the interface between normal (left) and dysplastic
(right) epithelium.
E. More marked reduction was observed in polypoid lesions, and
F. expression was lost in colorectal cancers.
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signiﬁcantly different from those found in the normal mucosa.
Consequently, the nonpolypoid transcriptome was somewhat
closer to that of the normal mucosa (Fig 1B). Many genes,
however, displayed altered expression in both types of lesions,
and in these cases the alterations were usually concordant in
terms of direction, but those observed in the nonpolypoid
lesions were less dramatic. In-depth evaluation of expression
intensity values for single genes across all the samples
(Supporting Information Fig 8) revealed that type IIa lesions
occupy an intermediate position between normal mucosa and
polypoid lesions. In other words, many genes exhibit progres-
sive up- or downregulation of transcription across the normal
mucosa!nonpolypoid! polypoid sequence.
These ﬁndings suggest that—in general—nonpolypoid
lesions might be less advanced on the road to cancer than
polypoid lesions. For example, loss of cell differentiation, a
hallmark of tumourigenesis, might be less pronounced in these
slightly elevated precursor lesions, as reﬂected by our ﬁndings
for many genes known to be involved in colorectal epithelial cell
differentiation (e.g. CA1, GCG, CLCA4, AQP8, and GUCA2A;
Fig 2B and Supporting Information Table 2) and also those for
TMIGD1. The latter genes’s association with cell differentiation
is suggested by our preliminary experiments, which showed that
the protein it encodes is expressed exclusively in the cell-
differentiation compartment of normal colorectal crypts.
Furthermore, its expression in Caco2 cells is restored by
conﬂuence-induced differentiation, an effect that was evident
mainly at the transcriptional level. Indeed, the increase in
TMIGD1 protein expressionwas farmoremodest. It is important
to recall, however, that Caco2 cells are a colon cancer cell line,
and although they can be forced to undergo some form of in vitro
differentiation mediated by transcriptional regulation resem-
bling that seen during normal-cell differentiation, they may also
retain feedback mechanisms that truncate all or part of this
process, e.g. by post-transcriptional suppression of the expres-
sion of one or more proteins associated with normal-cell
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Figure 7. TMIGD1 mRNA and protein expression studies in colon cancer
cells.
A. Western blot analysis of TMIGD1 protein expression in total cell extracts
from epithelial colonic crypts; SW480 colon cancer cells (which do not
express TMIGD1 mRNA—see legend to Fig 5) and SW480 cells transiently
transfected with the TMIGD1 cDNA (positive control). Proteins were
separated on a 12% polyacrylamide gel. TMIGD1 (apparent molecular
weight: 39 kDa) was not found in cell supernatants, and migration
accelerated (right-hand blot) when protein extracts were treated with the
deglycosylating enzyme PNGase F, behaviour suggestive of a nonsecreted
glycosylated protein. The nuclear protein MSH6 (nonsecreted and non-
glycosylated) was used as a control.
B. Immunocytochemistry. TMIGD1 expression in SW480 cells transiently
transfected with full-length TMIGD1 cDNA. The protein is highly expressed
in the perinuclear compartment (probably associated with the rough
endoplasmic reticulum) and cell membrane. Negative control: SW480 cells
transfected with the empty vector.
C. Real time quantitative RT-PCR assay of TMIGD1 mRNA levels in Caco2
colon cancer cells: Compared with proliferating cells (log phase), those
undergoing confluence-induced differentiation exhibited progressive
increases in TMIGD1 mRNA levels (8.7-fold and 23.6-fold increases on
post-confluence days 10 and 21, respectively). TMIGD1 (target) and GAPDH
(reference) coding regions were amplified. y-axis: [target concentration/
reference concentration] for sample/[target concentration/reference
concentration] for normal mucosa. Columns and bars represent mean
values and SD, respectively, of duplicate experiments. (Reference
expression was the mean observed in the normal mucosa sample, indi-
cated as 1).
D. Western blot assay of TMIGD1 protein expression in proliferating and
differentiating Caco2 cells. Upper panel (20-s exposure): Confluence-
induced differentiation is reflected by increasing expression of the
intestinal differentiation marker VIL1 on post-confluence days 10 and 21.
SW480 colon cancer cells: negative control for VIL1. Lower panel (12-min
exposure): In Caco2 cells undergoing confluence-induced differentiation
(post-confluence days 10 and 21), there was a slight increase in TMIGD1
protein expression (asterisk) compared with the undetectable expression
that characterized proliferating cells (log-phase). In the differentiating
colon-cancer cells (and in the normal mucosa positive control as well),
there was also a second lower molecular weight band (arrowhead)
possibly representing a TMIGD1 degradation product or isoform.
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differentiation. Therefore, the absence of substantially upregu-
lated TMIGD1 protein expression in differentiating Caco2 cells
does not exclude the possibility that this protein is associated
with normal colonocyte differentiation. Like the ascertained
differentiation genes listed above, TMIGD1 exhibited down-
regulation that was less marked in nonpolypoid precursors than
in polypoid lesions and cancers. Our ﬁndings contradict those of
Soetikno et al (Soetikno et al, 2008), but they are more
consistent with three recent studies of large series of superﬁcial
colorectal neoplasms, which revealed frequencies of submuco-
sal carcinoma in nondepressed, nonpolypolid lesions that were
similar to (Bianco et al, 2010; Park et al, 2008) or substantially
lower than (Kudo et al, 2008) those observed in polypoid
lesions.
It is important to note that endoscopic type IIa lesions are
more heterogeneous than type Ip lesions. Indeed, log2 expres-
sion intensity values for most genes (e.g. Fig 5A) displayed
somewhat higher standard deviations (average, 0.43 vs. 0.39 for
polypoid lesions) in the nonpolypoid group. This variability is in
part a reﬂection of the transcriptome differences between the
serrated and adenomatous subsets in this group (Fig 3A).
However, the subsets in this group are fairly small, which raises
the possibility of artefacts related to low statistical power and
data overﬁtting in the BGA. Conclusions regarding these
subtypes must, therefore, be regarded with caution. Never-
thless, the list of genes identiﬁed by BGA is highly enriched for
those whose dysregulated expression might be relevant to
colorectal tumourigenesis, and this list is, therefore, highly
useful for planning future studies.
The second difference between the two types of lesions was
qualitative. In polypoid lesions, GeneGO Metacore analysis
revealed a striking preponderance of dysregulated genes related
to cell-cycle regulation (Fig 4A). Important controllers of DNA
replication initiation (e.g. CDC6 and MCM7, Supporting
Information Fig 9) or S phase and mitotic checkpoints (e.g.
CCNA2, CDC2, CDC14A, DSCC1 and BUB1) were generally
upregulated in these lesions. In contrast, nonpolypoid lesions
typically displayed alterations in cell-survival pathways,
including the IGF-1 receptor signalling (known to confer
survival advantages; Samani et al, 2007) and those involved
in oxidative phosphorylation (including ubiquinone metabo-
lism). As shown in Supporting Information Fig 10, these ﬁndings
suggest that oxidative phosphorylation may be compromised to
some extent in nonpolypoid lesions. Partial or complete defects
of this type have been shown to induce resistance to apoptosis in
yeast (Harris et al, 2000) and mammalian cells (Tomiyama et al,
2006), and Jass has suggested that evasion of apoptosis may be
the pathogenic mechanism that gives rise to the glandular
serrated phenotype (Higuchi & Jass, 2004). It is tempting to
speculate that cell proliferation in polypoid and nonpolypoid
lesions is enhanced by different means: profound dysregulation
of the cell cycle in the former, hyperactivation of growth factor
signalling pathways and suppression of apoptosis in the latter. It
is important to recall, however, that polypoid and nonpolypoid
lesions also share important features, including the dysregula-
tion of pathways believed to play fundamental roles in the early
stages of colorectal transformation, such as those of the WNT
signalling, cytoskeleton remodelling and immune responses
(Fig 4B).
Our current data must be used with caution in formulating
conclusions on the malignant potentials of these preinvasive
lesions. Although polypoid and nonpolypoid lesions are clearly
different at the molecular level, tumourigenesis in each group
(the latter in particular) may well be a heterogeneous process.
This possibility needs to be explored in much larger series of
lesions that differ in stage (size) and segment of origin. We
intend to investigate this complicated process of transformation
with a two-pronged approach. The ﬁrst involves integration of
our transcriptomic ﬁndings with data from epigenomic,
metabolomic, and proteomic studies (currently ongoing in
our laboratory). The second entails the functional characteriza-
tion of single molecules whose expression is dramatically
altered in tumours. Our preliminary experiments point to
TMIGD1 as a possible cell-differentiation marker in the lower
intestine (and probably in the kidney and trachea as well),
whose expression is lost during cellular transformation. In silico
analysis indicates that TMIGD1 might play a role in cell
adhesion since it contains an immunoglobulin-like domain
similar to that found in adhesion molecules of the Ig-CAM
family. Our next step is to explore its functional roles and
determine whether its underexpression does indeed promote
progression of tumourigenesis in the intestinal epithelium.
MATERIALS AND METHODS
Endoscopic samples and RNA processing
The study protocol was approved by the local Ethics Committee, and
each participating tissue donor provided written informed consent. We
prospectively collected 42 precancerous colorectal lesions (each
accompanied by three biopsies of normal mucosa from the same
colon segment, but >2 cm from the lesion) during colonoscopy.
Twenty-five were slightly elevated (<2.5mm above the mucosal
surface) nonpolypoid lesions (type IIa or mixed lesions in the Paris
classification; Paris Workshop Participants, 2003); the other 17 were
pedunculated (type Ip) polypoid lesions. All but one (collected from a
patient with suspected attenuated familial polyposis) were sporadic
lesions.
Immediately after removal, a small sample (20–30mg) of epithelial
tissue was cut from each lesion, leaving the underlying muscularis
mucosae intact. The rest of the specimen was submitted for pathologic
analysis. (We used only lesions measuring 1 cm to ensure that the
sampling procedure would not interfere with the histologic diagnosis.)
This approach provided specimens with a high percentage of epithelial
cells without microdissection, which can diminish the quantity and
quality of the extracted RNA.
The tissue fragments (lesional epithelium and normal mucosa) were
stored in RNAlater (Ambion, Huntington, UK) and later homogenized.
Total RNA was extracted with the RNeasy Mini Kit (Qiagen, Valencia,
CA, USA) and its integrity verified by capillary gel electrophoresis
(Experion, BioRad, Hercules, CA, USA). Only RNAs with a 28S:18S
ribosomal RNA ratio between 1.5 and 2.2 were processed for
microarray analysis. After ribosomal RNA reduction, the RNA sample
was reverse-transcribed to cDNA with random hexamers tagged with
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a T7 promoter. The cDNA was amplified with T7 RNA polymerase and
subjected to a second cDNA synthesis. The sense-oriented, single-
stranded DNA produced with this step was then fragmented, biotin-
labelled and hybridized to the GeneChip Human Exon 1.0 ST array
(Affymetrix, Santa Clara, CA, USA). Arrays were analysed in the
Affymetrix GeneChip Scanner 3000 7G. Cell intensities (CEL files) were
measured with Affymetrix GeneChip Operating Software (GCOS) and
Affymetrix Expression Console Software was used for quality assess-
ment.
Raw expression data generated by the GCOS were preprocessed with
the Partek Genomics Suite (Partek, St. Louis, MO, USA) and analysed in
the R statistics environment with BioConductor packages (www.bio-
conductor.org). Probe expression intensity in each tissue sample was
subjected to background adjustment and normalization with the
robust multiarray analysis (RMA) algorithm (Irizarry et al, 2003). Raw
transcriptomic data have been deposited in GEO (accession number
GSE21962).
Microarray analysis
Our data (not shown) and others’ (Robinson & Speed, 2007) confirm
that the human exon array offers improved sensitivity and specificity
and more reliable detection of biological variability compared with
previous-generation arrays. The platform includes 5.4 million probes,
which target all the exons—annotated and predicted—in the
genome. Earlier platforms interrogated only the 30 end of mRNA
sequences, but exon arrays contain a set of four probes for each
putative exonic region. These probesets (1.4 million) can be virtually
reassembled into260,000 transcript clusters, one tenth of which are
likely to encode proteins. The so-called core probesets target exons
with RefSeq mRNA; those that target exons with EST evidence only are
referred to as extended probesets. The present analysis was limited to
data obtained with the 228,871 core probesets (17,881 transcript
clusters) plus the most completely annotated sets of the extended
category (74,732, corresponding to 5887 transcript clusters). All
23,768 of these well-annotated transcript clusters displayed above-
background expression levels in the 84 tissue samples we examined.
RMA-preprocessed expression data were subjected to unsupervised
analysis PCA and supervised multivariate analyses (BGA-based on CoA,
and RDA; Supporting Information; Baty et al, 2008; Culhane et al, 2002;
Quinn and Kenough, 2006; Ringner, 2008). PCA was used to obtain an
overview of the data structure (most obvious sample clusters, sample-to-
sample variance and homogeneity within sample groups) and to identify
outliers. BGA and RDA were used to cluster the samples and enrich the
data set for tumourigenesis-related genes, with respect to single (BGA) or
multiple clinical variables (RDA; details in Supporting Information). As for
RDA, it was used to prioritize clinical variables on the basis of their
associations with a specific sample cluster defined by similar gene
expression profiles, while BGA served to identify the genes in each cluster
whose expression was unique to that cluster, i.e. differentially expressed.
Although BGA and RDA are also used as classification tools or predictive
models, we used them exclusively with the aims specified above, mainly
because of our limited sample number.
GeneGo MetaCore software (www.genego.com) was then used to
identify the molecular processes most likely to be determinants of the
Research Article
Elisa Cattaneo et al.
The paper explained
PROBLEM:
Colorectal cancers arise from precancerous lesions with different
endoscopic andmicroscopic features. Thanks to improvements in
colonoscopy technique and technology, precancerous lesions are
being detected that were often missed in the past. This is
particularly true for nonpolypoid neoplasms, which currently
account for 30% of precancerous colorectal lesions. They are
often described as ‘flat’ since they tend to spread laterally
(instead of protruding into the gut lumen like the more familiar
colorectal polyp). A greater understanding of the molecular
features that distinguish polypoid and nonpolypoid precursors of
colorectal cancer is essential for their effective clinical
management and for cancer prevention.
RESULTS:
Using endoscopy, we collected biopsies from 42 precancerous
colorectal lesions representing the two most frequent endo-
scopic types: stalked colorectal polyps and slightly elevated,
nonpolypoid lesions—each with corresponding samples of
normal colorectal mucosa. Each sample was analysed to identify
its transcriptome—that is, messenger RNA expression levels for
each of the over 20,000 genes making up the human genome. As
expected, the transcriptomes of the precancerous lesions as a
whole differed markedly from that of the normal colorectal
mucosa, but the two types of precancerous lesions were also
clearly different from one another. Compared with the classical
polyps, the nonpolypoid lesions displayed fewer genes with
significantly altered expression, and when the same gene was
altered in both lesion types, the dysregulation in the polypoid
group was usually less dramatic. In addition, the expression
changes observed in the two groups often affected different
molecular pathways.
IMPACT:
Our findings indicate that slightly elevated nonpolypoid color-
ectal lesions progress towards cancer along a relatively distinct
route, exploiting certain specific molecular pathways along with
others shared with their polypoid counterparts (although the
dysregulation at this level is less severe). These data confirm
recently published clinical evidence suggesting that slightly
elevated nonpolypoid lesions may have a lower malignant
potential than classic colorectal polyps. With time (and growth),
however, these lesions, too, can transform into cancer, so high-
quality routine colonoscopy is encouraged to ensure their early
detection and removal.
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polypoid/nonpolypoid status of the lesions. This analysis was based on
the frequency of significant expression changes involving genes
related to the various processes (according to the Gene Ontology
database; Ashburner et al, 2000).
TMIGD1 expression studies
TMIGD1 TFBSs were predicted with TFBS track, which was downloaded
from the UCSC Genome Browser (http://genome.ucsc.edu/). The TFBS
locations and scores were generated with the TRANSFAC Matrix
Database (v7.0), which contains position-weight matrices for 398
TFBSs. This database was created by Biobase (http://www.biobase-
international.com/) and is available at TFBS track. The TMIGD1 gene
region analysed included 20 kb upstream and 10 kb downstream from
the transcription start site.
First-strand cDNA synthesis and quantitative real-time RT-PCR were
performed as previously described (Menigatti et al, 2009) with the
Roche LightCycler 480 real-time PCR system and a LightCycler 480
SYBR Green I Master kit (amplification conditions and primers
available on request).
Tissue sections were immunostained (24 h, 48C) for TMIGD1 expres-
sion, as previously described (Truninger et al, 2005). The primary
antibody (rabbit polyclonal anti-TMIGD1—HPA021946, Sigma–Al-
drich, St. Louis, MO, USA) was used at a 1:500 dilution. It was also
used to evaluate TMIGD1 expression in SW480 colon cancer cells.
Briefly, cells were seeded onto glass cover-slips, grown for an
appropriate period and fixed in 50% ethanol/50% methanol (15min
at RT). Fixed cells were permeabilized with 0.25% Triton X-100,
blocked with goat serum, and incubated 24h with anti-TMIGD1
antibodies. The cells were incubated with a secondary antibody
(labelled polymer-HRP anti-rabbit, DakoCytomation EnVisionþ
System-HRP; K4010) and the cytochemical detection performed by
using DAB (3,3-diaminobenzidine tetrahydrochloride).
Western blot analysis was performed as previously described
(Menigatti et al, 2009) on total cell extracts from epithelial colonic
crypts (isolated with the procedure reported by Fujimoto et al, 2002)
and two colon cancer cell lines (SW480 and Caco 2) obtained from the
Zurich Cancer Network cell-line repository. Rabbit polyclonal anti-
TMIGD1 antibodies (1:300; HPA021946) were purchased from Sigma–
Aldrich; mouse monoclonal anti-MSH6 antibodies (1:2000;
BD610918) were from BD Transduction Laboratories (San Jose, CA,
USA); mouse monoclonal anti-VIL1 antibodies (1:1000; MAB1639)
were from Chemicon International. Caco2 cells were cultured to
confluence (day 0) and harvested 10 and 21 days later to induce
differentiation. Medium was changed every 2 days (Papetti &
Augenlicht, 2011).
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